Ligand validation:3ZNK

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3ZNK designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3ZNK_NAG_C_1023	66%	57%	0.134	0.938	0.56	1.06	-	1	1	0	100%	0.9333
3ZNK_NAG_E_1023	61%	58%	0.136	0.924	0.5	1.1	-	1	1	0	100%	0.9333
3ZNK_NAG_A_1023	57%	58%	0.151	0.927	0.51	1.07	-	1	1	0	100%	0.9333
3ZNK_NAG_A_1165	44%	44%	0.165	0.892	0.75	1.38	-	2	0	1	100%	0.9333
3ZNK_NAG_D_1154	41%	53%	0.175	0.891	0.56	1.24	-	1	0	1	100%	0.9333
3ZNK_NAG_E_1165	35%	43%	0.168	0.854	0.77	1.43	-	2	0	0	100%	0.9333
3ZNK_NAG_C_1165	32%	47%	0.19	0.862	0.69	1.33	-	1	1	0	100%	0.9333
3ZNK_NAG_F_1154	24%	48%	0.206	0.834	0.44	1.53	-	1	0	1	100%	0.9333
3ZNK_NAG_B_1154	22%	55%	0.232	0.849	0.57	1.15	-	1	0	1	100%	0.9333
4BH0_NAG_A_1320	84%	50%	0.074	0.935	0.49	1.4	-	2	0	0	100%	0.9333
4CR0_NAG_A_1165	83%	51%	0.112	0.97	0.49	1.37	-	1	0	0	100%	0.9333
4KDQ_NAG_E_502	81%	59%	0.104	0.957	0.53	1.02	-	2	2	0	100%	0.9333
4BGZ_NAG_C_503	71%	53%	0.082	0.901	0.45	1.34	-	2	0	0	100%	0.9333
4K64_NAG_A_601	70%	61%	0.125	0.942	0.51	0.97	-	1	0	0	100%	0.9333
3H0C_NAG_A_794	100%	56%	0.021	0.995	0.61	1.08	-	1	0	0	100%	0.9333
5LDS_NAG_B_1007	100%	67%	0.022	0.995	0.48	0.79	-	-	0	0	100%	0.9333
5O5D_NAG_A_601	100%	65%	0.022	0.994	0.32	0.99	-	1	0	0	100%	0.9333
6MUG_NAG_G_629	100%	76%	0.022	0.994	0.35	0.58	-	-	0	0	100%	0.9333
3GXM_NAG_A_498	100%	45%	0.026	0.992	0.75	1.34	-	2	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.